CGRP receptor antagonists

1. A compound of the Formula I:

wherein:

Z is selected from:

A is C(R 2 );

B is O or S;

R 1 is selected from:

1) H, C 1 -C 6 alkyl, C 3-6 cycloalkyl and heterocycle, wherein the heterocyle is selected from azetidine, dioxane, dioxolane, morpholine, oxetane, piperazine, piperidine, pyrrolidine, tetrahydrofuran, and tetrahydropyran wherein said alkyl, cycloalkyl and heterocycle are unsubstituted or substituted with one or more substituents each independently selected from:

a) C 1-6 alkyl,

b) C 3-6 cycloalkyl,

c) phenyl, unsubstituted or substituted with 1-5 substituents each independently selected from R 4 ,

d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R 4 ,

and where heteroaryl is selected from:

imidazole, isoxazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, and thiazole;

e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R 4 , and where heterocycle is selected from: azetidine, dioxane, dioxolane, morpholine, oxetane, piperazine, piperidine, pyrrolidine, tetrahydrofuran, and tetrahydropyran;

f) (F) p C 1-3 alkyl,

g) halogen,

h) OR 4 ,

i) O(CH 2 ) s OR 4 ,

j) CO 2 R 4 ,

k) CN,

l) NR 10 R 11 ,

m) O(CO)R 4 ;

2) aryl or heteroaryl, selected from: phenyl, imidazole, isoxazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, and thiazole,

unsubstituted or substituted with one or more substituents each independently selected from:

a) C 1-6 alkyl,

b) C 3-6 cycloalkyl,

c) (F) p C 1-3 alkyl,

d) halogen,

e) OR 4 ,

f) CO 2 R 4 ,

g) (CO)NR 10 R 11 ,

h) SO 2 NR 10 R 11 ,

i) N(R 10 ) SO 2 R 11 ,

j) S(O) m R 4 ,

k) CN,

l) NR 10 R 11 , and

m) O(CO)R 4 ;

R 2 is selected from:

1) H, C 1 -C 6 alkyl, C 3-6 cycloalkyl and heterocycle, wherein the heterocyle is selected from azetidine, imidazolidine, imidazoline, isoxazoline, isoxazolidine, morpholine, oxazoline, oxazolidine, oxetane, pyrazolidine, pyrazoline, pyrroline, tetrahydrofuran, tetrahydropyran, thiazoline, and thiazolidine: wherein said alkyl, cycloalkyl and heterocycle are unsubstituted or substituted with one or more substituents each independently selected from:

a) C 1-6 alkyl,

b) C 3-6 cycloalkyl,

c) phenyl, unsubstituted or substituted with 1-5 substituents each independently selected from R 4 ,

d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R 4 ,

and where heteroaryl is selected from: benzimidazole, benzothiophene, furan, imidazole, indole, isoxazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, and triazole;

e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R 4 , and where heterocycle is selected from: azetidine, imidazolidine, imidazoline, isoxazoline, isoxazolidine, morpholine, oxazoline, oxazolidine, oxetane, pyrazolidine, pyrazoline, pyrroline, tetrahydrofuran, tetrahydropyran, thiazoline, and thiazolidine;

f) (F) p C 1-3 alkyl,

g) halogen,

h) OR 4 ,

i) O(CH 2 ) s OR 4 ,

j) CO 2 R 4 ,

k) CN,

l) NR 10 R 11 , and

m) O(CO)R 4 ; and

2) aryl or heteroaryl, selected from:

phenyl, benzimidazole, benzothiophene, furan, imidazole, indole, isoxazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, and triazole, unsubstituted or substituted with one or more substituents each independently selected from:

a) C 1-6 alkyl,

b) C 3-6 cycloalkyl,

c) (F) p C 1-3 alkyl,

d) halogen,

e) OR 4 ,

f) CO 2 R 4 ,

g) (CO)NR 10 R 11 ,

h) SO 2 NR 10 R 11 ,

i) N(R 10 ) SO 2 R 11 ,

j) S(O) m R 4 ,

k) CN,

l) NR 10 R 11 , and

m) O(CO)R 4 ,

where R 1 and R 2 , or any two independent R 2 , on adjacent atoms optionally join to form a ring selected from: C 5-7 cycloalkyl, heterocycle, aryl, and heteroaryl, in which the ring is unsubstituted or substituted with 1-10 substituents each independently selected from R 6 ;

R 10 and R 11 are independently selected from: H, C 1-6 alkyl, (F) p C 1-6 alkyl, C 3-6 cycloalkyl, aryl, heteroaryl, and benzyl, wherein said alkyl, cycloalkyl, aryl, heteroaryl and benzyl are unsubstituted or substituted with halogen, hydroxy or C 1 -C 6 alkoxy, where R 10 and R 11 optionally join to form a ring selected from: azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, which is ring is unsubstituted or substituted with 1-5 substituents each independently selected from R 4 ;

R 4 is independently selected from: H, C 1-6 alkyl, (F) p C 1-6 alkyl, C 3-6 cycloalkyl, aryl, heteroaryl and benzyl, wherein said alkyl, cycloalkyl, aryl, heteroaryl and benzyl are unsubstituted or substituted with halogen, hydroxy or C 1 -C 6 alkoxy;

W is O, NR 4 or C(R 4 ) 2 ;

X is C or S;

Y is O,(R 4 ) 2 , NCN, NSO 2 CH 3 or NCONH 2 , or Y is O 2 when X is S;

R 6 is H;

Q is independently selected from:

(1) ═C(R 7a )—,

(2) —C(R 7a ) 2 —,

(3) —C(═O)—,

(4) —S(O) m —,

(5) ═N—, and

(6) —N(R 7a )—;

T is independently selected from:

(1) ═C(R 7b )—,

(2) —C(R 7b ) 2 —,

(3) —C(═O)—,

(4) —S(O) m —,

(5) ═N—, and

(6) —N(R 7b )—;

R 7a and R 7b are each independently selected from H and phenyl, and R 7a and R 7b on adjacent caron atoms and the atoms to which they are attached optionally join to form a ring selected from phenyl or pyridine, which ring is unsubstituted;

p is 0 to 2q+1, for a substituent with q carbons;

m is 0, 1 or 2;

n is 0 or 1;

s is 1, 2 or 3;

and pharmaceutically acceptable salts and individual diastereomers thereof.

2. The compound of claim 1 having the Formula Ia:

and pharmaceutically acceptable salts and individual stereoisomers thereof.

3. The compound of claim 1 having the Formula Id:

and pharmaceutically acceptable salts and individual stereoisomers thereof.

4. The compound of claim 1 having the Formula Ie:

and pharmaceutically acceptable salts and individual stereoisomers thereof.

5. A compound of claim 1 of the formula:

wherein:

Z is selected from:

and pharmaceutically acceptable salts and individual stereoisomers thereof.

6. A compound selected from:

and pharmaceutically acceptable salts and individual stereoisomers thereof.

7. A pharmaceutical composition which comprises an inert carrier and the compound of claim 1 .